Product Name: Avatropag 20 Mg

Generic Name: Avatrombopag Maleate INN

Theraputic Category: Thrombopoietin (TPO) receptor agonists

Pak Size: 30 Tablets

Ziska pharmaceuticals

Origin: Bangladesh

Supplier: NER Pharma

Contact: +88 01776585142

Shipping By: EMS,DHL

Avatropag20Mg_Avatrombopag brand name Ziska Pharmacieuticals, is a medication that used for certain conditions that lead to thrombocytopenia (low platelets) such as thrombocytopenia associated with chronic liver disease in adults who are to undergo a planned medical or dental procedure. It was approved for medical use in the United States in May 2018, the European Union in June 2019, and Australia in January 2023

It acts as a thrombopoietin receptor agonist.

Pharmacology:

Avatrombopag is an orally bioavailable, small molecule TPO receptor agonist that

stimulates proliferation and differentiation of megakaryocytes from bone marrow

progenitor cells, resulting in an increased production of platelets. The median time to

maximal concentration (Tmax) occurred at 5 to 6 hours post-dose. Avatrombopag has

an estimated mean volume of distribution (%CV) of 180 L (25%). Avatrombopag is

greater than 96% bound to human plasma proteins. The mean plasma elimination

half-life (%CV) of avatrombopag is approximately 19 hours (19%). The mean (%CV) of

the clearance of avatrombopag is estimated to be 6.9 L/hr (29%). Avatrombopag is

primarily metabolized by cytochrome P450 CYP2C9 and CYP3A4. Fecal excretion

accounted for 88% of the administered dose, with 34% of the dose excreted as

unchanged avatrombopag. Only 6% of the administered dose was found in urine.

Indications:

Treatment of Thrombocytopenia in Patients with Chronic Liver Disease (CLD): It is

indicated for the treatment of thrombocytopenia in adult patients with chronic liver

disease who are scheduled to undergo a procedure.

Treatment of Thrombocytopenia in Patients with Chronic Immune

Thrombocytopenia (ITP): It is indicated for the treatment of thrombocytopenia in adult

patients with chronic immune thrombocytopenia who have had an insufficient response

to a previous treatment.